SNS Insider Black Friday Offer
Contrast Media/Contrast Agent Market

Contrast Media/Contrast Agent Market Size, Share & Segment by Type (Iodinated Contrast Media, Gadolinium-based Contrast Media, Microbubble Contrast Media, Barium-based Contrast Media), By Route of Administration (Oral Route, Intravascular Route, Rectal Route, Other Route of Administration), By Modality (X-ray/CT, Ultrasound, MRI), By Application (Interventional Radiology, Radiology, Interventional Cardiology), By Indication (Cardiovascular Disorders, Gastrointestinal Disorders, Cancer, Neurological Disorders, Musculoskeletal Disorders, Nephrological Disorders), By End User (Diagnostic Imaging Centers, Hospital, Clinics, & Ambulatory Surgery Centers), and by Regions | Global Market Forecast 2022-2028

Report Id: SNS/HC/1028 | May 2022 | Region: Global | 125 Pages

Report Scope & Overview:

The Contrast Media/Contrast Agent Market Size was valued at USD 4.20 billion in 2021, and expected to reach USD 5.45 billion by 2028, and grow at a CAGR of 3.8% over the forecast period 2022-2028.

Procedures, type, form, route of administration, and application have all been classified in the worldwide contrast media/ contrast agent in radiology market. The world market has been split into several countries while looking at different regions. The Contrast Media/ Contrast Agent Market's American area has been split into two parts:   North America and Latin America. In addition, the North American Contrast Media Industry has been divided into Canada and the United States. Eastern Europe and Western Europe are the two segments of the European market. Western Europe is also separated into the United Kingdom, Spain, Italy, Germany, France, and the rest of Western Europe. In addition, the Asia-Pacific Contrast Media/Contrast Agent Market has been divided into India, Japan, China, Australia, Latin Korea, and the rest of Asia-Pacific. Furthermore, the worldwide market's Middle East & African area has been segmented into Middle Eastern and African countries.

Contrast Media/Contrast Agent Market

The MRI contrast media/contrast agents market research identified the global market's recent growth and changes. In November 2019, the US Food and Drug Administration (FDA) approved GE Healthcare's gadolinium macrocyclic-based and Claris can (adulterate meglumine) anionic contrast agent injection for intravenous usage. Bayer AG has introduced the Medrad Stellant Flex CT injectable system in September 2019 to regulate contrast dose. In addition, due to the spending power of the target population, product demand is expanding. Hospitals and diagnostic centers, ambulatory surgery centers, medical device manufacturing firms, academic centers, medical device suppliers and retailers, and venture investors are among the target consumers.

MARKET DYNAMICS:

DRIVERS

  • The factors that encourage product development

  • Gaining popularity

RESTRAINTS

  • Associated side effects and allergic responses

OPPORTUNITIES

  • Introducing new technologies

  • Manufacture locally which brings price down

CHALLENGES

  • Scarcity of qualified professionals

  • Rise in price and side effect.

IMPACT OF COVID-19

Due to fewer patient visits to hospitals, the COVID-19 outbreak had a detrimental influence on the contrast media/contrast agent industry. Medical services frameworks have been seriously stressed because of the pandemic. To prevent the spread of the disease and conserve healthcare resources for COVID-19 patients, healthcare organizations and providers were told to halt performing optional surgical operations and medical evaluations. Accordingly, the volume of imaging cases in numerous radiology divisions dropped decisively. The contrast media/ contrast agent market has been impacted by decreased use of contrast media/ contrast agents due to a decline in the volume of elective and non-essential procedures, lower use of routine testing, lower capital spending by clients, and an abatement in research action because of lab terminations and decreased clinical testing. Many countries have begun to recover their economy, however the utilization rate of contrast media/contrast agents will take time to return to pre-pandemic levels. Moreover, any increase in COVID-19 infections could lead to further lockdowns, quarantine requirements, or other limitations in order to slow the spread of COVID-19, which could have a detrimental influence on market growth.

By Type

The contrast media/ contrast agent market has been impacted by lower use of contrast media/ contrast agents due to a decline in the volume of elective and non-essential procedures, lower utilization of routine testing, diminished capital spending by customers, and a reduce in research activity due to laboratory closures and reduced clinical testing. Many countries have started to recover their economies, but it will take time for the use of contrast media and contrast agents to return to pre-pandemic levels. Furthermore, any return in COVID-19 infections could result in further lockdowns, quarantine requirements, or other limitations in order to slow the spread of COVID-19, which could have a detrimental influence on market growth.

By Modality

The contrast media/ contrast agent market has been impacted by decreased use of contrast media/ contrast agents due to a decline in the quantity of elective and non-essential procedures, lower usage of routine testing, diminished capital spending by clients, and an abatement in research movement because of lab terminations and decreased clinical testing. Many countries have begun to recover their economies, but it will take time for contrast media/contrast agents utilization rates to return to pre-pandemic levels. Moreover, any increase in COVID-19 infections could result in further lockdowns, quarantine measures, or other limitations to slow COVID-19's spread, which could stifle market growth.

By Route of Administration

Oral, intravascular, rectal, and other modes of administration make up the contrast media/contrast agent industry. The vascular route is predicted to account for the majority of market share and grow at the fastest rate.

By Application

Radiology, interventional radiology, and interventional cardiology are the three segments of the contrast media/contrast agent market. The contrast media/contrast agent market was dominated by the radiology applications segment.

By Indication

Cardiovascular disorders, cancer, gastrointestinal disorders, musculoskeletal disorders, neurological disorders, and nephrological disorders are all segments of the contrast media/contrast agent industry. Cardiovascular illnesses had the largest market share and the fastest rate of increase.

By End User

Hospitals, clinics, ASCs, and diagnostic imaging centers make up the contrast media/contrast agent industry. The contrast media/contrast agent industry is dominated by hospitals, clinics, and ASCs. The increasing number of hospitals around the world is responsible for the large share.

Competitive Landscape

There are some major key players are as follows: Bayer AG, Spago Nanomedical AB, DAIICHI, Magnus Health, Bracco Diagnostic Inc., Jodas Expoim, GE Healthcare, Taejoon Pharm, Guerbet Group, Lantheus Medical Imaging Inc., NANOSCAN IMAGING, and Other Players.

Key Market Segments:

By Type

  • Iodinated Contrast Media

  • Gadolinium-based Contrast Media

  • Microbubble Contrast Media

  • Barium-based Contrast Media

By Route of Administration

  • Oral Route

  • Intravascular Route

  • Rectal Route

  • Other Route of Administration

By Modality

  • X-ray/CT

  • Ultrasound

  • MRI

By Application

  • Interventional Radiology

  • Radiology

  • Interventional Cardiology

By Indication

  • Cardiovascular Disorders

  • Gastrointestinal Disorders

  • Cancer

  • Neurological Disorders

  • Musculoskeletal Disorders

  • Nephrological Disorders

By End-User

  • Diagnostic Imaging Centers

  • Hospital, Clinics, & Ambulatory Surgery Centers

Contrast Media/Contrast Agent Market

REGIONAL ANALYSIS

Europe (Germany, the United Kingdom, France, Italy, Spain, and the Rest of Europe), Asia Pacific (Japan, China, India, and the Rest of Asia Pacific), Latin America, and the Middle East and Africa North America, followed by Europe, dominated the global contrast media/contrast agent market in 2020. The existence of prominent companies in the region, the high prevalence of chronic illnesses, the growing elderly population, and the increasing use of minimally invasive procedures all contribute to the North American market's size.

REGIONAL COVERAGE:

North America

  • USA

  • Canada

  • Mexico

Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • The Netherlands

  • Rest of Europe

Asia-Pacific

  • Japan

  • south Korea

  • China

  • India

  • Australia

  • Rest of Asia-Pacific

The Middle East & Africa

  • Israel

  • UAE

  • South Africa

  • Rest of Middle East & Africa

Latin America

  • Brazil

  • Argentina

  • Rest of Latin America

 

Contrast Media/Contrast Agent Marke Report Scope:
Report Attributes Details
Market Size in 2021 US$ 4.20 Billion
Market Size by 2028 US$ 5.45 Billion
CAGR CAGR of 3.8% From 2022 to 2028
Base Year 2021
Forecast Period 2022-2028
Historical Data 2017-2020
Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments • By Application (Dental Implantology, Oral and Maxillofacial Surgery, Orthodontics, Endodontics, General Dentistry, Temporomandibular Joint (TMJ) Disorders, Periodontics, Forensic Dentistry)
• By Patient Position (Standing Position, Seated Position, Supine Position)
• By End-Use (Hospitals & Others, Dental Clinics)
Regional Analysis/Coverage North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
Company Profiles Bayer AG, Spago Nanomedical AB, DAIICHI, Magnus Health, Bracco Diagnostic Inc., Jodas Expoim, GE Healthcare, Taejoon Pharm, Guerbet Group, Lantheus Medical Imaging Inc., NANOSCAN IMAGING
DRIVING FACTORS • The factors that encourage product development
• Gaining popularity
Restraints • Associated side effects and allergic responses


Frequently Asked Questions (FAQ) :

Contrast Media/Contrast Agent Market expected to reach USD 5.45 billion by 2028.

Latin America, and the Middle East and Africa North America, followed by Europe, dominated the global contrast media/contrast agent market.

The market is divided into six segments and the segments are By Type, By Route of Administration, By Modality, By Application, By Indication, and By End User

The challenges faced by contrast media/contrast agent Market is Scarcity of qualified professionals, and Rise in price and side effect.

key drivers of the contrast media/contrast agent Market is the factors that encourage product development, and Gaining popularity


Table of Contents

 

1. Introduction

1.1 Market Definition

1.2 Scope

1.3 Research Assumptions

 

2. Research Methodology

 

3. Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges

 

4. Impact Analysis

4.1 COVID 19 Impact Analysis

 

5. Value Chain Analysis

 

6. Porter’s 5 forces model

 

7. PEST Analysis

 

8. Contrast Media/Contrast Agent Market Segmentation, by Type

8.1 Iodinated Contrast Media

8.2 Gadolinium-based Contrast Media

8.3 Microbubble Contrast Media

8.4 Barium-based Contrast Media

 

9. Contrast Media/Contrast Agent Market Segmentation, by Route of Administration

9.1 Oral Route

9.2 Intravascular Route

9.3 Rectal Route

9.4 Other

 

10. Contrast Media/Contrast Agent Market Segmentation, By Modality

10.1 X-ray/CT

10.2 Ultrasound

10.3 MRI

 

11. Contrast Media/Contrast Agent Market Segmentation, By Application

11.1 Interventional Radiology

11.2 Radiology

11.3 Interventional Cardiology

 

12. Contrast Media/Contrast Agent Market Segmentation, By Indication

12.1 Cardiovascular Disorders

12.2 Gastrointestinal Disorders

12.3 Cancer

12.4 Neurological Disorders

12.5 Musculoskeletal Disorders

12.6 Nephrological Disorders

 

13. Contrast Media/Contrast Agent Market Segmentation, By End User

13.1 Diagnostic Imaging Centers

13.2 Hospital, Clinics, & Ambulatory Surgery Centers

 

14. Regional Analysis

14.1 Introduction

14.2 North America

142.1 USA

142.2 Canada

142.3 Mexico

14.3        Europe

14.3.1 Germany

14.3.2 UK

14.3.3 France

14.3.4 Italy

14.3.5 Spain

14.3.6 The Netherlands

14.3.7 Rest of Europe

14.4        Asia-Pacific

14.4.1 Japan

14.4.2 South Korea

14.4.3 China

14.4.4 India

14.4.5 Australia

14.4.6 Rest of Asia-Pacific

14.5        The Middle East & Africa

14.5.1 Israel

14.5.2 UAE

14.5.3 South Africa

14.5.4 Rest

14.6        Latin America

14.6.1 Brazil

14.6.2 Argentina

14.6.3 Rest of Latin America

 

15. Company Profiles

15.1 Bayer AG

15.1.1 Financial

15.1.2 Products/ Services Offered

15.1.3 SWOT Analysis

15.1.4 The SNS view

15.2 Spago Nanomedical AB

15.3 DAIICHI

15.4 Magnus Health

15.5Bracco Diagnostic Inc.

15.6 NANOSCAN IMAGING

15.7 GE Healthcare

15.8 Jodas Expoim

15.9 Taejoon Pharm

15.10 Guerbet Group

15.11 Lantheus Medical Imaging Inc.

 

16. Competitive Landscape

16.1 Competitive Benchmark

16.2 Market Share analysis

16.3 Recent Developments

 

17. Conclusion

 

An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of a good and accurate research report and selecting the best methodology to complete the research is the toughest part. Since the research reports, we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach a stage wherein we can provide our clients best and most accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brainstorming sessions to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.

 

The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research as the name suggests is a research process wherein, we collect data through readily available information. In this process, we use various paid and unpaid databases to which our team has access and gather data through the same. This includes examining listed companies’ annual reports, Journals, SEC filling, etc. Apart from this, our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various universities as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content-specific facts that can be sued to solve specific problems. Since the collected data is fresh and first-hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply sides of the industry to make sure we land an accurate judgment and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses, and observation of on-field participants. The below-mentioned chart should give a better understanding of part 1 of the primary interview.

Part 2: In this part of the primary research the data collected via secondary research and part 1 of the primary research is validated with the interviews with individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence center, our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real-time.

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but is not limited to getting rid of the many typos, duplication of numbers, or missing any important information. The people involved in this process include technical content writers, research heads, and graphics people. Once this process is completed the title gets uploaded on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.